02 July 2026
: Case report 
Tacrolimus-Induced Thrombotic Microangiopathy in a Kidney Transplant Recipient After Treatment for Acute Allograft Rejection
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Adverse events of drug therapy, Clinical situation which can not be reproduced for ethical reasons
Yen-Hao Liao ABDEF 1*, Ming-Yi Huang DF 1DOI: 10.12659/AJCR.953247
Am J Case Rep 2026; 27:e953247
Figure 2 Temporal relationship between tacrolimus exposure and the development of microangiopathic hemolytic anemia. The figure illustrates the time course of tacrolimus administration, corresponding trough concentrations (green line), platelet count (orange bars), hemoglobin level (red line), and serum creatinine (blue line). Abbreviation: TMA, thrombotic microangiopathy.